Zymeworks (ZYME) – Investment Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Zymeworks (NASDAQ: ZYME):

• 10/28/2025 – Zymeworks was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 10/24/2025 – Zymeworks was upgraded by analysts at Wells Fargo & Company to a “hold” rating.
• 10/19/2025 – Zymeworks was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 10/14/2025 – Zymeworks was upgraded by analysts at HC Wainwright from a “hold” rating to a “strong-buy” rating.
• 10/11/2025 – Zymeworks was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 10/9/2025 – Zymeworks was upgraded by analysts at B. Riley to a “strong-buy” rating.
• 10/8/2025 – Zymeworks had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Zymeworks had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.